Q-Line Biotech IPO Listing 2026 – Allotment, Demat Credit & BSE SME Debut

The Q-Line Biotech IPO delivered a strong listing performance on the NSE, opening at ₹452 per share and recording a listing gain of 31.78%, driven by heavy subscription demand and strong investor sentiment. The IPO also saw significant interest in the grey market, with the GMP last reported at ₹129, indicating high pre-listing expectations.

On the subscription side, the IPO was heavily oversubscribed at 102.42 times overall by the final day. Category-wise demand was extremely strong, with the retail portion subscribed 71.44 times, the NII segment at 145.98 times, and the QIB category at 123.94 times, reflecting broad-based investor enthusiasm across all segments.

Image Reference : https://www.nseindia.com/

Q-Line Biotech IPO Listing gains  

Company Overview

Q-Line Biotech is an Indian In-Vitro Diagnostics (IVD) company founded in 2008 with its headquarters located in Lucknow, Uttar Pradesh. The company is engaged in the manufacturing, development, and supply of diagnostic products, laboratory equipment, rapid testing solutions, and pathology instruments for the healthcare industry. Under the “Make in India” initiative, Q-Line Biotech focuses on domestic production of advanced healthcare products including hematology reagents, magnetic beads, gold nanoparticles, ELISA kits, urine testing strips, and multiple biochemistry diagnostic solutions.

The company caters to hospitals, diagnostic centers, medical institutions, pathology laboratories, and healthcare organizations across India and international markets. Q-Line Biotech has expanded its global footprint by exporting products to over 50 countries. The company maintains strong quality standards and operates with certifications such as ISO 9001:2015 and ISO 13485:2016. Through continuous innovation, modern manufacturing practices, and a focus on accessible healthcare diagnostics, Q-Line Biotech continues to strengthen its presence in the medical diagnostics and laboratory solutions sector.